Zilucoplan

Molecular mass: 3,562.229 g/mol PubChem compound: 133083018

Therapeutic indications

Zilucoplan is indicated for:

Myasthenia gravis in patients who are anti-acetylcholine receptor antibody positive

Population group: only adults (18 years old or older)

Zilucoplan is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients weighting <56 kg 16.6 mg once daily, for patients weighting ≥56 - <77 kg 23 mg once daily and for patients weighting ≥77 kg 32.4 kg once daily

Contraindications

Zilucoplan is contraindicated in the following cases:

Lactation

Patients who are not currently vaccinated against Neisseria meningitidis

Meningococcal vaccines

Patients with unresolved Neisseria meningitidis infection

Meningococcal infectious disease

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.